- Home
- VRAX vs XBIO Comparison
VRAX vs XBIO Comparison
Compare VRAX & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- XBIO
- Stock Information
- Founded
- VRAX 2013
- XBIO N/A
- Country
- VRAX United Kingdom
- XBIO United States
- Employees
- VRAX N/A
- XBIO N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- VRAX Health Care
- XBIO Health Care
- Exchange
- VRAX Nasdaq
- XBIO Nasdaq
- Market Cap
- VRAX 7.8M
- XBIO 6.3M
- IPO Year
- VRAX 2022
- XBIO N/A
- Fundamental
- Price
- VRAX $2.37
- XBIO $4.06
- Analyst Decision
- VRAX
- XBIO Hold
- Analyst Count
- VRAX 0
- XBIO 1
- Target Price
- VRAX N/A
- XBIO N/A
- AVG Volume (30 Days)
- VRAX 198.4K
- XBIO 22.9K
- Earning Date
- VRAX 02-05-2025
- XBIO 11-12-2024
- Dividend Yield
- VRAX N/A
- XBIO N/A
- EPS Growth
- VRAX N/A
- XBIO N/A
- EPS
- VRAX N/A
- XBIO N/A
- Revenue
- VRAX $84,872.00
- XBIO $2,523,427.00
- Revenue This Year
- VRAX $5,169.18
- XBIO N/A
- Revenue Next Year
- VRAX $66.97
- XBIO N/A
- P/E Ratio
- VRAX N/A
- XBIO N/A
- Revenue Growth
- VRAX 7.03
- XBIO 7.15
- 52 Week Low
- VRAX $0.60
- XBIO $2.78
- 52 Week High
- VRAX $9.00
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- VRAX 64.60
- XBIO 47.20
- Support Level
- VRAX $1.51
- XBIO $3.92
- Resistance Level
- VRAX $1.98
- XBIO $4.27
- Average True Range (ATR)
- VRAX 0.18
- XBIO 0.27
- MACD
- VRAX 0.03
- XBIO -0.05
- Stochastic Oscillator
- VRAX 98.85
- XBIO 19.09
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.